Anesiva — Algorx Pharmaceuticals — Merger or Acquisition (October 2005)
41 slides from Anesiva's merger presentation, Oct 6, 2005
Slide 1: Creating a Late-Stage Company Focused on Pain Management and Inflammation
Filed by Corgentech Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: AlgoRx Pharmaceuticals, Inc. Commission File No. of Subject Company: 000-51146 *** *** *** The following is a slide prese
Slide 2: Forward Looking Statements
FORWARD This “expect,” intended proposed materially merger; segments market contained Corgentech not 2 statement. topresentation place acceptance. approval to merger, grow “estimate,” in from identify and undue LOOKING Corgentech’s as AlgoRx results of includes and anticipated; reliance Actual such
Slide 3: Forward Looking Statements (Additional Information)
FORWARD Additional available documents Investor Corgentech, merger Corgentech Stockholders, 3 above. transaction transaction. Relations because Information filed Inc. described AlgoRx LOOKING which intends with they at involving Information was and the the above. will and to STATEMENTS email their S
Slide 4: Creating a Late-Stage Company
CREATING Four Each All Phase Statistically Second Expect Development Marketing, Financial 4 discovery product drug 3product to Phase program strength file has can commercialization, significantly LATE-STAGE development NDA and 3potential unique be approval trial ALGRX commercialized commercial devel
Slide 5: Agenda
Terms of merger agreement Product pipeline of combined company ALGRX 3268: positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense AGENDA 5
Slide 6: Terms of Merger Agreement
TERMS Stock At company, Combined Corgentech Board Richard and John Management Dr. James close Ronald added McLaughlin Transaction and Huang Brewer, of OF respectively soon Management management merger, Burch, and MERGER newly after AlgoRx Dr. as current Corgentech elected Charles CEO deal AGREEMENT
Slide 7: Agenda
Terms of merger agreement Product pipeline of combined company ALGRX 3268: positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense AGENDA 7
Slide 8: Product Pipeline
PRODUCT PRECLINICAL Pre-procedural Post-surgical Morton’s NF-kB Tendonitis Atopic ALGRX Cutaneous * 8 dermatitis Decoy Does 3268 4975 1207 neuroma neuropathic PIPELINE pain not *analgesia PHASE reflect (eczema) pain comprehensive 1(004) (003) PHASE 2 PHASE list of3trials currently underway
Slide 9: ALGRX 3268 Topical Local Anesthesia
ALGRX TOPICAL Reduction Indication Two Sterile, Within No 9 vasoconstriction Phase 1pre-filled, 3268- minute of LOCAL 3 trials painwith needle-free associated being ANESTHESIA with duration conducted good with disposable of dermal about venipunctures Keytolerability 10 desirable delivery minutesand
Slide 10: ALGRX 3268 Onset Versus EMLA
Reduction Package EMLA 1 Time 60 ALGRX Data VAS, 10 3 5 Time ALGRX 10 mmInsert 0 -10 from after -20 after in 3268 Pain Phasefor1from EMLA administration, 3268 -30 trial administration, has an Venipuncture in onset 272 minutes oneafter adults minutes within Administration minute, whereas EMLA is labe
Slide 11: Phase 1 Trial: Antecubital Fossa Design
PHASE U.S. Design Number 272 Normal Population Identify Objectives Criteria Efficacy: Safety: 11 subjects single skin for healthy an 1ofReduction TRIAL: optimal subjects center, evaluation evaluations enrolled subjects ANTECUBITAL randomized, configuration infor pain for of 240either erythema, oneva
Slide 12: Phase 1 Results: Antecubital Fossa
PHASE Efficacy For 0.25mg/20bar Safety Either The Based Conclusion 12 all higher 0.25mg on endpoint 3Iendpoint device efficacy RESULTS: pressure vs. orconfigurations, 0.5mg 20bar and ofANTECUBITAL tolerability, 40 placebo lidocaine bar had for n=80 higher and recommendation all p=0.0217 time lower F
Slide 13: Phase 1 Trial: Back of Hand Design
PHASE U.S. Design Number 183 Normal Population Identify Objectives Criteria Efficacy: Safety: 13 subjects single skin for healthy an 1ofReduction TRIAL: optimal subjects center, evaluation evaluations enrolled subjects randomized, BACK configuration infor pain for of 159 OF either erythema, onevalua
Slide 14: Phase 1 Results: Back of Hand
PHASE Efficacy For Duration Safety Both Based Conclusion 14 0.50mg/40bar the 0.50mg/40bar on endpoints 0.50mg/20bar Iendpoint of efficacy RESULTS: effect and is device and shown BACK device tolerability, 0.50mg/20bar configuration, from OF configuration, HAND 1 either to 5were minutes the device red
Slide 15: ALGRX 3268 Development Protocols
ALGRX Protocol Total Evaluate Pharmacokinetics Lidocaine Primary Achieved Antecubital Children Back 15 2,213 of Hand Endpoint Age 3268 Circulating 3Achieved 574 500 Fossa Group Adults Achieved Children DEVELOPMENT Safety Adults Children andPhase Primary 1and Primary 183 2 1306 145 Efficacy Patients
Slide 16: Agenda
Terms of merger agreement Product pipeline of combined company ALGRX 3268: positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense AGENDA 16
Slide 17: Phase 3 Identical Protocols 003 and 004
PHASE IDENTICAL U.S. Design Number 500-600 Pediatric Population Confirm Objectives Primary Assessment 17 multicenter, 3’s: endpoint of subjects efficacy, subjects subjects of 003 PROTOCOLS pain AND randomized, in safety ofon each either 004 venipuncture and study gender tolerability double-blind, (a
Slide 18: Phase 3 Results (003)
PHASE Primary Statistically 574 ALGRX Placebo No Well 18 significant patients tolerated = 3endpoint 3268 RESULTS 285 significantly at safety group patients sixachieved U.S. = issues (003) (ages 289 clinical less (p=0.007) patients 3-18) pain trialon(ages sites needle 3-18) insertion in treated group
Slide 19: Projected Timeline for ALGRX 3268
PROJECTED Data Clinical Reviewed Regulatory File Registration Product 19 NDA fromapproval in as second 1H06 aTIMELINE drug in Phase by 1H07 the 3 trial FOR FDA(004) ALGRX Analgesics expected 3268 andwithin Acutetwo Caremonths Division
Slide 20: ALGRX 4975 Overview
ALGRX Capsaicin Administered site Single provide weeks Non-opioid Only noxious with Does nerve motor Activates Blocks 20 ofC-neurons reduces not fibers skills pain to administration noxious analgesia pain 4975 months affect the Overview based important associated VR1 long-term locally –other pain VR
Slide 21: ALGRX 4975 Development Protocols
ALGRX Protocol 4975 Phase Postsurgical DEVELOPMENT 2Total Pain Patients 40Primary Endpoint Status Bunion Total Removal Hernia Knee Repair Cholecystectomy Neuropathic Morton’s Surgery 48 Replacement Pain Neuroma 240 60 Time 2 182 2 Magnitude Magnitude 160 and Magnitude to Rescue Magnitude ofDuration
Slide 22: Eczema: Large Unmet Need
ECZEMA: Unmet Existing Safety Strong Shorter 22 issues preclinical medical time therapies LARGE to with proof need data are long-term UNMET of not with concept satisfactory NF- application NEED B Decoy (steroids ofshowing steroids, and effective calcineurin especially treatment in inhibitors) childr
Slide 23: NF-kB Decoy for Eczema
NF-k Two Safety, Multiple Physician US Four 0.25% Trial 0.50% 1.00% Placebo 21 Ex-US Three days B Phase 20DECOY cohorts tolerability (75 endpoints and 151/2 patients cohorts Trial daily of FOR patients) patient trials and patients treatment (120 40 ECZEMA tounderway assessments assess PK preliminary
Slide 24: ALGRX 1207
ALGRX IND-enabling New Deep, Neuropathic Dermatological Surgical 24 chemical rapid incisions 1207 penetration pain studies class surgery ofunderway local of theanesthetic skin and for longtopical duration analgesia of action Addresses a wide variety of procedures including:
Slide 25: New Local Anesthetic
New80 25 local Percent 100 -120 Time, ALGRX -110 Lidocaine Unique -60 anesthetic 60-100 minutes 60 -90 non-clinical complete 01207 40 20 allowing 1200anesthesia 180 results 240 300 rapid andmodels in relevant 360 420 complete topical anesthesia without exotic delivery
Slide 26: Agenda
Terms of merger agreement Product pipeline of combined company ALGRX 3268: positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense AGENDA 26
Slide 27: Prevalence and Patient Numbers
PREVALANCE PATIENT PrevalenceNUMBERS post-operative OF PAIN of diabetic back HIV pain INpain SEVEN pain 208,996,00075,068,000 MAJOR COUNTRIES Prevalence 27 of areand AIDS osteoarthritic Above indications Source: Datamonitor pain allneuropathy targets 847,000 pain 13,243,000 of46,610,000 Corgentech p
Slide 28: 3268: Local Anesthesia Market Dynamics
3268: TOPICAL ANESTHESIA Strong pressure Current 28 focus market on cost of dynamics MARKET pain reduction LOCAL management provide and DYNAMICS patient an including excellent through-put treatment opportunity in hospitals protocols for aFundamental and fast guidelines acting, easy market Increase t
Slide 29: Underserved Target Market
UNDERSERVED Target Only Low slow lack Faster 29 of utilization onset 2.1MM onset market promotion ofofout action action, ofofof topical MARKET 18MM currently needleless local venipuncture available anesthetics injection drugs procedures and (12%promotion of pediatric in children’s willprocedures) al
Slide 30: 3268: Clinical Practice of Topical Local Anesthetics in Hospitals
3268: ERs Many Existence Nurses Some Parents Patient Previously 30 CLINICAL hospitals and rather andof apply treated parent sometimes established than offer topical PRACTICE anxiety children physicians topical children local protocols levels frequently local usually anesthetics, OF over are anesthet
Slide 31: 3268: Phased Marketing Approach
3268: PHASED MARKETING APPROACH 31
Slide 32: ALGRX 4975: Post-Operative Pain Market
ALGRX US 50% Patients’ Europe Pain 32 post-operative in indicate hospital also post-surgical 4975: under lack POST-OPERATIVE associated of pain treats adequate pain market: post-operative with experiences pain $1.7 increased control PAIN billion pain between length MARKET Virtually 1993 of stay, all
Slide 33: ALGRX 4975: High Volume Surgeries
ALGRX Procedure Caesarean 4975: Hysterectomy Episiotomy Arthroplasty Hip Volume HIGH Section 417,699 (knee) Replacement, VOLUME SURGERIES (all) 1,163,893 1,042,715 399,139 343,554 total/partial CABG Colorectal 33 316,471 resection 280,969
Slide 34: Current Post-Op Pain Medications
CURRENT Use Epidurals Nausea, Opioids Sedation Decreased Concern Unacceptable Non-narcotics ALGRX Unlikely Site-specific No Long-acting 34 addiction declining vomiting, about 4975 may tobowel be POST-OP with with potential anesthesia limit significantly contra-indicated addiction function single lim
Slide 35: NF-kB Decoy: Eczema Market
NF-?B Eczema Patient Severe 5.2M Moderate Mild 1. Sources: 2. 35 International 60% 15.6M 10% DECOY: Population Prevalence market 30%31.1M Consensus isECZEMA comprised Segmented of Atopic Conference MARKET of Dermatitis bymild, Mild,moderate on Moderate inAtopic Japanese and Dermatitis and severe Adu
Slide 36: NF-kB Decoy: Sales of Protopic and Elidel
NF-kB $200 Total $300 $400 Dollars $500 $600 $700 (millions) $800 1999 36 $100 DECOY: 2000 $0Health, 2001 Corticosteroids Source: IMS Rx2002 SALES Protopic 20042003(U.S.) 2004 $900 Elidel
Slide 37: ALGRX 1207: Target Market
ALGRX1207: Deep, ($ 2001 37 in millions) rapid 2002penetration 2003 TARGET $45 2004E $107of $215 MARKET 2005E the skin $300 (IMS) Long $400(IMS) duration (IMS) of action (Endo)Addresses (Endo) neuropathic pain market Non-exotic delivery
Slide 38: Agenda
Terms of merger agreement Product pipeline of combined company ALGRX 3268: Positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense AGENDA 38
Slide 39: Deal Timeline
DEAL Both Merger S-4 Shareholder 39 and boards TIMELINE requires documents related vote have joint stockholder expected approved toProxy be filed to Statement merger approval occur in coming in lateweeks 2005 / early 2006
Slide 40: Agenda
Terms of merger agreement Product pipeline of combined company ALGRX 3268: positive Phase 3 data Commercial potential of products Deal timeline Why this merger makes sense AGENDA 40
Slide 41: Why This Merger Makes Sense
WHY Four Each All Phase Statistically Second Expect Development Marketing, Financial 41 discovery product drug THIS 3product to Phase program strength file has can commercialization, significantly MERGER development NDA and 3potential unique be approval trial ALGRX commercialized commercial developm
Algorx Pharmaceuticals — Merger or Acquisition (October 2005) on 6ix